1. Scrip

Big Pharma At The Senate: When It Comes To Yes Or No Questions, There Are Still A Few Maybes

 
• By Jessica Merrill

Our question-by-question infographic shows how Rx executives exhibited enough finesse to avoid any embarrassing sound bites at the Senate Finance Committee hearing on drug pricing.

YES and NO acceptance and rejection symbols vector for vote, election choice. Brush painted symbolic approval icons in square frames. Tick and cross signs, check marks graphic design. - Vector

The seven big pharma leaders who testified at the Senate Finance Committee hearing on drug pricing Feb. 26 largely stuck together in responding to questions, a united front that particularly stands out when looking at the executives' responses to the yes-or-no questions posed by senators.

Those types of questions could have presented a potential pitfall: a video clip of all seven admitting that yes, drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.